Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 monotherapy or combination in advanced CRC
NCT05799820Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706 in colorectal carcinoma (CRC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Objective Response Rate. Started Sep 2022; status: recruiting.
02
Drugs
QL1706
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT05799820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799820.